Avoid common mistakes on your manuscript.
Correction to: Adv Ther https://doi.org/10.1007/s12325-019-01052-y
In the original publication the colors of Fig. 2 have been switched. The corrected Fig. 2 is given below
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
About this article
Cite this article
Glassberg, M.K., Nathan, S.D., Lin, CY. et al. Correction to: Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. Adv Ther 36, 2927–2929 (2019). https://doi.org/10.1007/s12325-019-01082-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-019-01082-6